PBU The Pension Fund of Early Childhood & Youth Educators Takes Position in Guardant Health, Inc. $GH

PBU The Pension Fund of Early Childhood & Youth Educators purchased a new stake in Guardant Health, Inc. (NASDAQ:GH) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 335,854 shares of the company’s stock, valued at approximately $34,304,000. Guardant Health makes up approximately 1.2% of PBU The Pension Fund of Early Childhood & Youth Educators’ investment portfolio, making the stock its 9th largest holding.

A number of other hedge funds also recently made changes to their positions in the stock. Allworth Financial LP boosted its stake in shares of Guardant Health by 19.5% in the 3rd quarter. Allworth Financial LP now owns 844 shares of the company’s stock valued at $53,000 after purchasing an additional 138 shares in the last quarter. Eastern Bank boosted its stake in shares of Guardant Health by 6.9% in the 4th quarter. Eastern Bank now owns 2,160 shares of the company’s stock valued at $221,000 after purchasing an additional 139 shares in the last quarter. Danske Bank A S boosted its stake in shares of Guardant Health by 20.0% in the 4th quarter. Danske Bank A S now owns 1,200 shares of the company’s stock valued at $123,000 after purchasing an additional 200 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Guardant Health by 20.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,242 shares of the company’s stock valued at $127,000 after purchasing an additional 209 shares in the last quarter. Finally, IFP Advisors Inc boosted its position in Guardant Health by 34.6% during the 4th quarter. IFP Advisors Inc now owns 844 shares of the company’s stock worth $86,000 after buying an additional 217 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Stock Performance

Guardant Health stock opened at $125.61 on Friday. Guardant Health, Inc. has a 52-week low of $40.35 and a 52-week high of $134.28. The firm has a 50 day moving average price of $99.39 and a two-hundred day moving average price of $101.08. The firm has a market cap of $16.66 billion, a price-to-earnings ratio of -37.05 and a beta of 1.61.

Insider Activity

In other Guardant Health news, CEO Amirali Talasaz sold 210,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $109.89, for a total transaction of $23,076,900.00. Following the completion of the transaction, the chief executive officer owned 1,886,504 shares in the company, valued at approximately $207,307,924.56. This trade represents a 10.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Chris Freeman sold 24,406 shares of the firm’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $118.67, for a total transaction of $2,896,260.02. Following the transaction, the insider owned 60,034 shares of the company’s stock, valued at approximately $7,124,234.78. The trade was a 28.90% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 350,238 shares of company stock worth $38,538,372. 5.60% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities research analysts recently commented on GH shares. Wolfe Research started coverage on shares of Guardant Health in a research report on Tuesday. They set an “outperform” rating and a $150.00 target price on the stock. Leerink Partners lifted their target price on shares of Guardant Health from $170.00 to $180.00 and gave the stock an “outperform” rating in a research report on Friday, February 20th. Citigroup lifted their target price on shares of Guardant Health from $135.00 to $150.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. The Goldman Sachs Group started coverage on shares of Guardant Health in a research report on Friday. They set a “buy” rating and a $165.00 target price on the stock. Finally, Evercore upgraded shares of Guardant Health from an “in-line” rating to an “outperform” rating and set a $160.00 target price on the stock in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $137.80.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.